Atlas Trials

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

Clinical trial NCT05160272 · COMPLETED

Trial details

NCT number
NCT05160272
Sponsor
The Deutsche Diabetes Forschungsgesellschaft e.V.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Type2 Diabetes
Start date
2022-01-07
Primary completion
2024-12-17
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.